Board of the Pension Protection Fund Takes $850,000 Position in DaVita Inc. $DVA

Board of the Pension Protection Fund purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 6,400 shares of the company’s stock, valued at approximately $850,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. boosted its stake in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. MAI Capital Management boosted its position in DaVita by 23.4% during the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after buying an additional 83 shares during the period. NewEdge Advisors LLC grew its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of DaVita by 1.4% in the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after acquiring an additional 94 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of DaVita by 1.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,184 shares of the company’s stock valued at $1,451,000 after acquiring an additional 122 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 0.8%

DVA opened at $115.18 on Friday. The company has a market cap of $8.13 billion, a price-to-earnings ratio of 11.86, a price-to-earnings-growth ratio of 0.88 and a beta of 1.00. The stock has a fifty day simple moving average of $121.38 and a two-hundred day simple moving average of $131.48. DaVita Inc. has a 12-month low of $113.97 and a 12-month high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. During the same period in the prior year, the company earned $2.59 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DVA shares. UBS Group reissued a “buy” rating on shares of DaVita in a research note on Monday. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Barclays cut their price target on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. Finally, TD Cowen decreased their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a report on Monday, November 3rd. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $148.00.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.